Search

Displaying results 9321 - 9330 of 9870 in total
  1. Drug

    SHR-A1904

    go.drugbank.com/drugs/DB18702
    Investigational

    SHR-A1904 is under investigation in clinical trial NCT04877717 (A Study of SHR-A1904 in Patients With Advanced Solid Cancer).

  2. Drug

    Olezarsen

    go.drugbank.com/drugs/DB18728
    ApprovedInvestigational

    [A264888,A264893] Olezarsen is conjugated to a ligand containing three N-acetyl-galactosamine (GalNAc) residues to enable its delivery to hepatocytes. … Olezarsen is an antisense oligonucleotide that targets the messenger RNA (mRNA) for apolipoprotein C-III (APOC3, apoC-III),[L52033] which is a key regulator of triglyceride levels in plasma, in the liver

    Synonyms: DNA, D(P-THIO)((2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETHYL))M5RU-M5C-T-T-G-T-M5C-M5C-A-G-M5C-(2'-O-(2-METHOXYETHYL), -D-GALACTOPYRANOSYLOXY)HEXYLAMINO)-3-OXOPROPOXYMETHYL))METHYL)AMINO-5-OXOPENTANAMIDO)HEXYL))PHOSPHO)-2'-O-(2-METHOXYETHYL)-P-THIOADENYLYL-(3'-O->5'-O)-2'-O-(2-METHOXYETHYL)-P-THIOGUANYLYL-(3
  3. Drug

    HTPEP-001

    go.drugbank.com/drugs/DB18730
    Experimental

    HTPEP-001 is a novel peptide that works to inhibit the activation of transforming growth factor beta (TGF-β). It is being investigated for the treatment of fibrosis.[A263527]

  4. Drug

    Pegulicianine

    go.drugbank.com/drugs/DB18731
    ApprovedInvestigational

    Pegulicianine itself is a prodrug comprising three main fragments, one of which contains a fluorescence quencher that keeps the parent molecule optically inactive. … [L50537] The _in vivo_ enzymatic cleavage of pegulicianine results in two optically active fragments that emit a fluorescent signal that can be detected using a fluorescence imaging device.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    BVX-001

    go.drugbank.com/drugs/DB18733
    Experimental

    BVX001 is a a novel, first-in-class CD33/CD7-directed antibody-drug conjugate.

  6. Drug

    Nogapendekin alfa

    go.drugbank.com/drugs/DB18740
    ApprovedInvestigational

    Nogapendekin alfa is a human IL-15N72D variant. … It is one of the active ingredients in Anktiva, a combination product also containing [inbakicept], where a single inbakicept is complexed with two nogapendekin alfa components.

    Synonyms: Human interleukin 15 (72-aspartic acid) (human il-15 n72>d isoform), Il-15n72d:il-15rec-su/fc soluble complex i
  7. Drug

    Avizakimab

    go.drugbank.com/drugs/DB18842
    Investigational

    Avizakimab is under investigation in clinical trial NCT03371251 (Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care).

  8. Drug

    Elsubrutinib

    go.drugbank.com/drugs/DB18850
    Investigational

    Elsubrutinib is under investigation in clinical trial NCT04451772 (A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants

  9. Drug

    Plutavimab

    go.drugbank.com/drugs/DB18856
    Investigational

    Plutavimab is under investigation in clinical trial NCT04900428 (Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)).

  10. Drug

    Galegenimab

    go.drugbank.com/drugs/DB18860
    Investigational

    Galegenimab is under investigation in clinical trial NCT03972709 (A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to